TL;DR: Kernal Biologics is a Y Combinator Summer 2020 startup Kernal is creating mRNA 2.0 therapies that work in specific cells, currently active with a team of 20.
Kernal is creating mRNA 2.0 therapies that work in specific cells
Last verified:
Kernal Bio is a biotech company pioneering mRNA 2.0 immunotherapies. We leverage selective mRNA-LNP technology to treat cancer and autoimmune diseases with precision, ensuring targeted cell delivery and minimal off-target effects. Our KR-402 program achieves over 90% delivery efficiency with T-cell-targeted LNPs, enabling direct CAR-T programming within the body and resulting in B-cell depletion within a week. Kernal Bio is led by a team with experience from MIT, Harvard, Merck, and BMS, boasting three FDA-approved therapies and over 120 patents. Based in Cambridge, MA, we are backed by Hummingbird Ventures, Amgen Ventures, HBM, and even NASA. With roots at MIT, Harvard and Biopharma, Kernal’s management team has deep expertise in mRNA therapeutics space. CEO Yusuf Erkul, M.D., M.B.A. is…
Built by LemStudio
Yes. Kernal Biologics was funded by Y Combinator in the Summer 2020 batch. Kernal is creating mRNA 2.0 therapies that work in specific cells
Kernal Bio is a biotech company pioneering mRNA 2.0 immunotherapies. We leverage selective mRNA-LNP technology to treat cancer and autoimmune diseases with precision, ensuring targeted cell delivery and minimal off-target effects. Our KR-402 program achieves over 90% delivery efficiency with T-cell-targeted LNPs, enab…
Kernal Biologics was part of Y Combinator's Summer 2020 batch.
Kernal Biologics has a team of 20 people according to Y Combinator's directory.
Kernal Biologics is currently listed as Active with a team of 20 in Y Combinator's directory.
Loading interactive view…